Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inozyme Pharma (INZY)
NASDAQ:INZY
Inozyme Pharma (INZY) Stock Price & Analysis
290 Followers
INZY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.69 - $7.80
Previous Close$5.33
Volume128.45K
Average Volume (3M)377.26K
Market Cap
$329.69M
Enterprise Value$210.17M
Total Cash (Recent Filing)$166.15M
Total Debt (Recent Filing)$46.63M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Aug 07, 2024EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding61,855,509
10 Day Avg. Volume330,606
30 Day Avg. Volume377,262
Standard Deviation0.31
R-Squared0.06
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.96
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.97
Forecast
1Y Price Target
$16.25Price Target Upside204.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Inozyme Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessInozyme reported positive topline data from the Phase 1/2 clinical trial in adults with ABCC6 Deficiency, meeting all study objectives.
Market PotentialINZY's lead program in ENPP1 deficiency addresses a market with high unmet need, limited to no competition, and significant pricing power.
Regulatory MilestoneThe FDA has granted Fast Track Designation for INZ-701 for the treatment of ABCC6 Deficiency.
Bears Say
Drug Development ChallengesINZY faces well-known challenges in rare disease drug development, including real world patient identification and disease awareness, few/no regulatory comparisons, and limited data on certain indications.
FDA ViewsThe data was in a small number of patients and there are questions about FDA’s views on a pivotal trial design.
Mixed Update ReactionINZY shares reacted negatively post the recent mixed update on ABCC6, and there are some questions regarding the program including endpoint selection and regulatory buy-in.
---
Ownership Overview
55.09% Insiders
14.34% Mutual Funds
7.87% Other Institutional Investors
22.70% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INZY FAQ
What was Inozyme Pharma’s price range in the past 12 months?
Inozyme Pharma lowest stock price was $2.69 and its highest was $7.79 in the past 12 months.
What is Inozyme Pharma’s market cap?
Currently, no data Available
When is Inozyme Pharma’s upcoming earnings report date?
Inozyme Pharma’s upcoming earnings report date is Aug 07, 2024 which is in 16 days.
How were Inozyme Pharma’s earnings last quarter?
Inozyme Pharma released its earnings results on May 07, 2024. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.36 by -$0.02.
Is Inozyme Pharma overvalued?
According to Wall Street analysts Inozyme Pharma’s price is currently Undervalued.
Does Inozyme Pharma pay dividends?
Inozyme Pharma does not currently pay dividends.
What is Inozyme Pharma’s EPS estimate?
Inozyme Pharma’s EPS estimate is -$0.4.
How many shares outstanding does Inozyme Pharma have?
Inozyme Pharma has 61,855,510 shares outstanding.
What happened to Inozyme Pharma’s price movement after its last earnings report?
Inozyme Pharma reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.36. Following the earnings report the stock price went down -5.738%.
Which hedge fund is a major shareholder of Inozyme Pharma?
Among the largest hedge funds holding Inozyme Pharma’s share is Woodline Partners LP. It holds Inozyme Pharma’s shares valued at 7M.
---
Inozyme Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.25 (204.88% Upside)
$16.25 (204.88% Upside)
Blogger Sentiment
Bullish
INZY Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 589.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.25%
12-Months-Change
Fundamentals
Return on Equity
-69.41%
Trailing 12-Months
Asset Growth
24.79%
Trailing 12-Months
Company Description
Inozyme Pharma
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
---
INZY Stock 12 Month Forecast
Average Price Target
$16.25
▲(204.88% Upside)
Technical Analysis
Best Analysts Covering INZY
1 Year
1 Year Success Rate
9/12 ratings generated profit
1 Year Average Return
+27.35%
reiterated a buy rating 3 months ago
Copying Joseph Stringer's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +27.35% per trade.
---